SI: the cash flow

MyFinsight

The latest financial statement is for the year ending 2025-12-31.

Cash Flow	2025-12-31
Gross profit	36,202
General and administrative	26,234
Sales and marketing	23,545
Medical education	4,989
Research and development	7,731
Interest/other expense	-14,062
Net loss	-40,359
Depreciation and amortization	3,208
Amortization of debt discounts	253
Credit losses, net of recoveries	153
Loss on disposal of long-lived assets	-100
Stock compensation expense	996
Realized gain on marketable securities	404
Change in fair value of warrant liabilities and series e purchase option	11,975
Change in fair value of convertible notes, net	2,217
Other	0
Trade accounts receivable	3,299
Inventory	7,636
Prepaid expenses	1,087
Accounts payable	3,369
Other current assets and liabilities	-1,902
Net cash used in operating activities	-28,612
Fixed asset purchases	7,408
Purchases of marketable securities	119,491
Sales of marketable securities	31,302
Net cash provided (used) in investing activities	-95,597
Proceeds from exercise of common stock options	919
Proceeds from exercise of preferred stock warrants	455
Proceeds from series e convertible preferred stock, net of issuance cost	39,508
Proceeds from the issuance of convertible notes, net of issuance costs	39,863
Proceeds from ipo, net of commissions and issuance costs	64,212
Net cash provided in financing activities	144,957
Net change in cash for period	20,748
Cash and cash equivalents, beginning of year	6,123
Cash and cash equivalents, end of year	26,871

Unit: Thousand (K) dollars (except for numbers of shares and EPS).